Bio-Imaging joins GE MRI therapy effort
GE Medical Systems willget a helping hand in its interventional MRI program from Bio-ImagingTechnologies. GE has enlisted the West Trenton, NJ, firm to providedata management and technical consulting services for its image-guidedtherapy program. GE
GE Medical Systems willget a helping hand in its interventional MRI program from Bio-ImagingTechnologies. GE has enlisted the West Trenton, NJ, firm to providedata management and technical consulting services for its image-guidedtherapy program.
GE unveiled its interventional MRI unit, Signa MRT, at lastyear's Radiological Society of North America meeting, where itwas shown in panel displays as a work-in-progress (SCAN 11/17/93).Signa MRT is a 0.5-tesla superconducting magnet with a gap inthe center of the scanner that allows physicians to access patientsfor interventional procedures.
GE's image-guided therapy program uses focused ultrasound totreat breast lesions. Under the agreement signed with GE, Bio-ImagingTechnologies will participate in the program by assisting GE inthe monitoring, processing and digital management of medical imagesand related clinical information. Bio-Imaging will use its Bio/ImageBasemedical image-enabled database to manage MRI images, mammogramsand electronic documents, and to facilitate regulatory submissionand review of data gathered in the program.
Considering Breast- and Lesion-Level Assessments with Mammography AI: What New Research Reveals
June 27th 2025While there was a decline of AUC for mammography AI software from breast-level assessments to lesion-level evaluation, the authors of a new study, involving 1,200 women, found that AI offered over a seven percent higher AUC for lesion-level interpretation in comparison to unassisted expert readers.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
